EGFR and head and neck squamous cell carcinoma: As an EGFR‐targeted drug, nimotuzumab has been shown to improve survival in HNSCC in retrospective small‐sample studies, and a phase III randomized controlled study from India indicated that it can improve PFS, but there was no statistical difference in OS.30